2022: Dotarem® is celebrating 140 million doses administered globally

2022: Dotarem® is celebrating 140 million doses administered globally

With more than 140 million doses administered globally1, Dotarem® safety profile continuously be proven by real-world experience2

We understand patients’ benefit and safety are always the first priority for you: Dotarem® is the 1st Gd chelate to be macrocyclic in the market since 19893, and, consequently, has high molecular stability, thus, minimizing the risk of free gadolinium release into the body4,5,6. Dotarem® also shows a low adverse event rate from clinical studies to real-world experience7.

Thanks to YOU, we are proud to share that Dotarem® has reached more than 140 million administered doses in over 80 countries. We thank you for being with us during the journey. We hope with your participation, we are able to benefit more patients in the future.

Click the video below to learn more!

For more information about Dotarem®, please see the Full Prescribing Information. For current and complete prescribing information refer to the package insert and/or contact your local Guerbet organization. (*) Indications, presentations, and marketing authorization holders may differ from country to country. Reporting of suspected adverse reactions is important as it helps to continuously assess the benefit-risk balance. Therefore, Guerbet encourages you to report any adverse reactions to your health authorities or to our local Guerbet representative.

P22001120 – February 2022

References

  1. Data on file, Guerbet internal data (2021)
  2. Philippe Soyer et al., Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study. J Magn Reson Imaging. 2017 Apr; 45(4): 988–997.
  3. Val M. Runge et al., The developmental history of the gadolinium chelates as intravenous contrast media for magnetic resonance. Invest Radiol. 2011 Dec;46(12):807-16.
  4. M. Idée et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol. 2006; 2 0(6): 563-576.
  5. A. Kirchin et al. Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging. 2003; 14(5): 426-435
  6. Moshe Rogosnitzky and Stacy Branch. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals. 2016; 29: 365–376.
  7. Eric de Kerviler et al, Adverse Reactions to Gadoterate Meglumine: Review of Over 25 Years of Clinical Use and More Than 50 Million Doses. Invest Radiol. 2016 Sep;51(9):544-51.